Latest / Applied Clinical Trials
ACT Brief: Evaluating Evidence for Individualized Therapies, Clinical Trial Reporting Compliance, and TIL Therapy Merger
In today's ACT Brief, we explore how FDA evaluates effectiveness for ultra-rare individualized therapies, the agency's enforcement push for mandatory trial result reporting, and Obsidian's merger backed by $350 million to advance next-generation TIL cell therapy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.